72.40
price up icon2.19%   1.55
after-market 시간 외 거래: 74.40 2.00 +2.76%
loading
전일 마감가:
$70.85
열려 있는:
$71.17
하루 거래량:
29,946
Relative Volume:
0.35
시가총액:
$77.49M
수익:
$7.10M
순이익/손실:
$-39.43M
주가수익비율:
-77.02
EPS:
-0.94
순현금흐름:
$-46.50M
1주 성능:
-6.64%
1개월 성능:
-10.14%
6개월 성능:
-86.68%
1년 성능:
-90.34%
1일 변동 폭
Value
$71.00
$74.40
1주일 범위
Value
$69.02
$83.49
52주 변동 폭
Value
$7.26
$543.38

스프루스 바이오 Stock (SPRB) Company Profile

Name
명칭
Spruce Biosciences Inc
Name
전화
(415) 655-4168
Name
주소
611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO
Name
직원
20
Name
트위터
Name
다음 수익 날짜
Name
최신 SEC 제출 서류
Name
SPRB's Discussions on Twitter

Compare SPRB vs VRTX, REGN, ARGX, ALNY, ONC

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
SPRB
Spruce Biosciences Inc
72.40 75.84M 7.10M -39.43M -46.50M -0.94
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.92 116.41B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
785.51 81.05B 14.34B 4.50B 3.77B 41.56
Biotechnology icon
ARGX
Argen X Se Adr
811.45 50.76B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.16 43.76B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ONC
Beone Medicines Ltd Adr
353.92 38.40B 4.98B 69.60M 525.67M 0.5198

스프루스 바이오 Stock (SPRB) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-12-23 개시 Oppenheimer Outperform
2025-12-03 업그레이드 Leerink Partners Market Perform → Outperform
2025-10-28 업그레이드 Citizens JMP Mkt Perform → Mkt Outperform
2024-12-11 다운그레이드 JMP Securities Mkt Outperform → Mkt Perform
2024-12-11 다운그레이드 Oppenheimer Outperform → Perform
2024-03-14 다운그레이드 Guggenheim Buy → Neutral
2024-03-14 다운그레이드 H.C. Wainwright Buy → Neutral
2024-03-14 다운그레이드 Ladenburg Thalmann Buy → Neutral
2024-03-14 다운그레이드 Leerink Partners Outperform → Market Perform
2024-03-14 다운그레이드 RBC Capital Mkts Outperform → Sector Perform
2024-02-21 개시 Guggenheim Buy
2021-12-17 개시 Oppenheimer Outperform
2021-12-10 개시 The Benchmark Company Speculative Buy
2021-11-16 다운그레이드 SVB Leerink Outperform → Mkt Perform
2021-07-19 개시 H.C. Wainwright Buy
2021-04-26 재개 Credit Suisse Outperform
2020-11-03 개시 Cowen Outperform
2020-11-03 개시 Credit Suisse Outperform
2020-11-03 개시 RBC Capital Mkts Outperform
2020-11-03 개시 SVB Leerink Outperform
모두보기

스프루스 바이오 주식(SPRB)의 최신 뉴스

pulisher
Feb 06, 2026

Spruce Biosciences: TA-ERT’s Promising Long-Term Data and Priority Review Voucher Upside Underpin Reiterated Buy and $220 Target - TipRanks

Feb 06, 2026
pulisher
Feb 05, 2026

Experimental enzyme therapy stabilizes skills for 6 years in fatal disorder - stocktitan.net

Feb 05, 2026
pulisher
Feb 04, 2026

Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team - BioSpace

Feb 04, 2026
pulisher
Feb 03, 2026

Spruce Biosciences Makes Two SVP Appointments - Contract Pharma

Feb 03, 2026
pulisher
Feb 03, 2026

Spruce Biosciences (NASDAQ:SPRB) Shares Up 0.6%Time to Buy? - MarketBeat

Feb 03, 2026
pulisher
Jan 29, 2026

Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™ - BioSpace

Jan 29, 2026
pulisher
Jan 28, 2026

Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium - Investing News Network

Jan 28, 2026
pulisher
Jan 21, 2026

Harbour BioMed Exercises Warrant to Acquire 3.8% of Spruce Biosciences Inc. - intellectia.ai

Jan 21, 2026
pulisher
Jan 21, 2026

Big-Pharma Partner Harbour BioMed Boosts Stake In Spruce Biosciences - Benzinga

Jan 21, 2026
pulisher
Jan 20, 2026

Harbour BioMed Acquires Stake in U.S. Partner Spruce Biosciences, Signaling Strategic Shift in Chinese Biotech - IndexBox

Jan 20, 2026
pulisher
Jan 20, 2026

Harbour BioMed Acquires 3.8% of Spruce Biosciences, Enhancing Strategic Partnership - intellectia.ai

Jan 20, 2026
pulisher
Jan 19, 2026

Harbour BioMed Expands Stake in Spruce Biosciences (SPRB) - GuruFocus

Jan 19, 2026
pulisher
Jan 19, 2026

Harbour BioMed Exercises Agreement to Buy Spruce Biosciences Common Stock - Contract Pharma

Jan 19, 2026
pulisher
Jan 18, 2026

Harbour BioMed Acquires 3.8% Stake in Spruce Biosciences (SPRB) - Intellectia AI

Jan 18, 2026
pulisher
Jan 18, 2026

Harbour BioMed Acquires 3.8% Stake in Spruce Biosciences - Intellectia AI

Jan 18, 2026
pulisher
Jan 18, 2026

Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deep - GuruFocus

Jan 18, 2026
pulisher
Jan 18, 2026

Harbour BioMed Exercises Warrant To Acquire Stake In Spruce Biosciences - Nasdaq

Jan 18, 2026
pulisher
Jan 18, 2026

HBM Holdings Deepens Ties With Spruce Biosciences via Warrant Exercise - TipRanks

Jan 18, 2026
pulisher
Jan 18, 2026

Harbour BioMed buys into Spruce to back new hormone disorder drug - Stock Titan

Jan 18, 2026
pulisher
Jan 18, 2026

Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration - Barchart.com

Jan 18, 2026
pulisher
Jan 18, 2026

Harbour BioMed takes stake in Spruce Biosciences - MSN

Jan 18, 2026
pulisher
Jan 18, 2026

HBM Lifts Spruce Biosciences Stake to About 3.8% After Warrant Exercise - marketscreener.com

Jan 18, 2026
pulisher
Jan 14, 2026

Spruce Biosciences (SPRB) Price Target Increased by 10.02% to 235.11 - Nasdaq

Jan 14, 2026
pulisher
Jan 11, 2026

Spruce Biosciences, Inc. (NASDAQ:SPRB) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

Jan 11, 2026
pulisher
Jan 08, 2026

Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital - BioSpace

Jan 08, 2026
pulisher
Jan 08, 2026

Spruce Biosciences secures up to $50 million in growth capital from Avenue Capital - marketscreener.com

Jan 08, 2026
pulisher
Jan 08, 2026

Spruce Biosciences Signs Multiple Financing Agreements - TradingView — Track All Markets

Jan 08, 2026
pulisher
Jan 01, 2026

Spruce Biosciences (SPRB) price target increased by 55.76% to 213.69 - MSN

Jan 01, 2026
pulisher
Dec 29, 2025

MSN Money - MSN

Dec 29, 2025
pulisher
Dec 28, 2025

Spruce Biosciences assumed with a buy at HC Wainwright - MSN

Dec 28, 2025
pulisher
Dec 27, 2025

Spruce Biosciences (NASDAQ:SPRB) Lowered to Sell Rating by Wall Street Zen - MarketBeat

Dec 27, 2025
pulisher
Dec 24, 2025

Equities Analysts Offer Predictions for SPRB FY2025 Earnings - MarketBeat

Dec 24, 2025
pulisher
Dec 24, 2025

Spruce Biosciences initiated with an Outperform at Oppenheimer - Yahoo Finance

Dec 24, 2025
pulisher
Dec 23, 2025

Oppenheimer Initiates Coverage on SPRB with "Outperform" Rating - GuruFocus

Dec 23, 2025
pulisher
Dec 23, 2025

Coty downgraded, Spruce Biosciences initiated: Wall Street's top analyst calls - Yahoo Finance

Dec 23, 2025
pulisher
Dec 23, 2025

Oppenheimer starts Spruce Biosciences with "outperform" rating on rare disease strength - TradingView — Track All Markets

Dec 23, 2025
pulisher
Dec 23, 2025

Oppenheimer initiates coverage on Spruce Biosciences stock with Outperform rating - Investing.com Australia

Dec 23, 2025
pulisher
Dec 23, 2025

Oppenheimer Initiates Coverage of Spruce Biosciences (SPRB) with Outperform Recommendation - Nasdaq

Dec 23, 2025
pulisher
Dec 23, 2025

Revenue per share of Spruce Biosciences, Inc. – NASDAQ:SPRB - TradingView — Track All Markets

Dec 23, 2025
pulisher
Dec 22, 2025

Spruce Biosciences stock rating resumed at Buy by H.C. Wainwright - Investing.com Nigeria

Dec 22, 2025
pulisher
Dec 22, 2025

HC Wainwright Reaffirms Buy Rating for Spruce Biosciences (NASDAQ:SPRB) - MarketBeat

Dec 22, 2025
pulisher
Dec 22, 2025

SPRB Stock: HC Wainwright & Co. Initiates Coverage with Buy Rati - GuruFocus

Dec 22, 2025
pulisher
Dec 21, 2025

Spruce Biosciences, Inc.(NasdaqCM: SPRB) added to S&P TMI Index - marketscreener.com

Dec 21, 2025
pulisher
Dec 20, 2025

With Spruce Biosciences Stock Sliding, Have You Assessed The Risk? - Trefis

Dec 20, 2025
pulisher
Dec 17, 2025

[Form 4] SPRUCE BIOSCIENCES, INC. Insider Trading Activity - Stock Titan

Dec 17, 2025
pulisher
Dec 17, 2025

Spruce Biosciences CEO reports RSU vesting and option repricing | SPRB SEC FilingForm 4 - Stock Titan

Dec 17, 2025
pulisher
Dec 17, 2025

Spruce Biosciences, Inc. (NASDAQ:SPRB) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat

Dec 17, 2025
pulisher
Dec 17, 2025

Spruce Biosciences Appoints Keli Walbert as Director - The Globe and Mail

Dec 17, 2025

스프루스 바이오 (SPRB) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$30.90
price down icon 0.23%
$44.65
price up icon 1.25%
$108.39
price up icon 5.48%
$106.62
price up icon 1.02%
$149.86
price down icon 0.77%
biotechnology ONC
$353.92
price up icon 1.99%
자본화:     |  볼륨(24시간):